Muna Therapeutics ApS: Financial statements 2020
CVR: 41142871
Source: annual report 2020, Danish Business Authority
22/01/2020 – 31/12/2020
Muna Therapeutics ApS (CVR 41142871) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -7,345,098 and a net result of DKK -7,382,109. Equity in the 2020 report amounted to DKK 16,657,741. The solvency ratio was 68.5%. The company had 3 employees in the financial year.
- Gross Profit
- DKK -7,345,098
- Profit/Loss
- DKK -7,382,109
- Equity
- DKK 16,657,741
- Total Assets
- DKK 24,321,118
- Employees
- 3
Official annual report
How creditworthy is Muna Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 29, 2020, Stefan Lohmer has joined the board of directors of Muna Therapeutics ApS.
As of October 12, 2020, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Muna Therapeutics ApS.
As of October 12, 2020, A/S PSE 17 NR. 1056 has stepped down as auditor of Muna Therapeutics ApS.
As of September 16, 2020, Joachim Pold Vilstrup has joined the board of directors of Muna Therapeutics ApS.
As of September 16, 2020, Simon Glerup Pedersen has left the board of directors of Muna Therapeutics ApS.
As of June 3, 2020, Anders Mørkeberg Hinsby has joined the board of directors of Muna Therapeutics ApS.
As of June 3, 2020, Camilla Petrycer Hansen has joined the board of directors of Muna Therapeutics ApS.
As of June 3, 2020, Simon Glerup Pedersen has joined the board of directors of Muna Therapeutics ApS.
As of June 3, 2020, Morten Døssing has joined the board of directors of Muna Therapeutics ApS.
As of June 3, 2020, Peder Søndergaard Madsen has left the board of directors of Muna Therapeutics ApS.
About Muna Therapeutics ApS
Muna Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Michel Marcel A. Detheux. The board consists of Donald William Nicholson (chair), Camilla Petrycer Hansen, Cillian King and Eileen Elizabeth McGuire. The company's owners include Novo Holdings A/S, Sanofi Foreign Participations B.V. and Axxam S.p.A.. The company has 18 employees (2026). In 2025, the company reported a gross profit of DKK -60,636,000 and a net result of DKK -125,695,000 compared with DKK -173,625,357 the year before. Equity in the 2025 report amounted to DKK -120,338,000.